EE04466B1 - Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitorid - Google Patents
Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitoridInfo
- Publication number
- EE04466B1 EE04466B1 EEP200000385A EEP200000385A EE04466B1 EE 04466 B1 EE04466 B1 EE 04466B1 EE P200000385 A EEP200000385 A EE P200000385A EE P200000385 A EEP200000385 A EE P200000385A EE 04466 B1 EE04466 B1 EE 04466B1
- Authority
- EE
- Estonia
- Prior art keywords
- protease inhibitors
- aspartyl protease
- sulphonamide derivatives
- sulphonamide
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/998,050 US6436989B1 (en) | 1997-12-24 | 1997-12-24 | Prodrugs of aspartyl protease inhibitors |
PCT/US1998/004595 WO1999033815A1 (en) | 1997-12-24 | 1998-03-09 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000385A EE200000385A (et) | 2001-12-17 |
EE04466B1 true EE04466B1 (et) | 2005-04-15 |
Family
ID=25544691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000385A EE04466B1 (et) | 1997-12-24 | 1998-03-09 | Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitorid |
Country Status (43)
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122000A1 (en) * | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
AR020590A1 (es) | 1998-06-02 | 2002-05-22 | Cadus Pharmaceutical Corp | 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden |
GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
AU6329599A (en) * | 1998-09-28 | 2000-04-17 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester |
GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
AU2002302363B2 (en) | 2001-02-14 | 2008-05-01 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors |
SK288232B6 (sk) | 2001-04-09 | 2014-11-04 | Tibotec Pharmaceuticals Ltd. | 2-(substituovaný amino)benzoxazolsulfónamidový derivát, jeho aplikácie ako liečiva, farmaceutická kompozícia s jeho obsahom a spôsob in vitro inhibície retrovírusovej replikácie |
EP1387842B1 (en) | 2001-05-11 | 2009-04-22 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors |
US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
WO2003048120A2 (en) | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
AR037797A1 (es) * | 2001-12-12 | 2004-12-01 | Tibotec Pharm Ltd | Combinacion de inhibidores de proteasa dependientes del citocromo p450 |
CN101973998A (zh) | 2001-12-20 | 2011-02-16 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物 |
EA007468B1 (ru) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
CA2470964C (en) | 2001-12-21 | 2013-07-02 | Tibotec Pharmaceuticals Ltd. | Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
TWI332956B (en) * | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
NZ536496A (en) | 2002-05-17 | 2006-06-30 | Tibotec Pharm Ltd | Broadspectrum substituted benzisoxazole sulfonamide HIV protease inhibitors |
US7199148B2 (en) | 2002-08-14 | 2007-04-03 | Tibotec Pharmaceuticals Ltd | Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
CA2425031A1 (en) * | 2003-04-01 | 2004-10-01 | Smithkline Beecham Corporation | Pharmaceutical compositions |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
DK1628685T3 (da) | 2003-04-25 | 2011-03-21 | Gilead Sciences Inc | Antivirale phosphonatanaloge |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
CN101786991A (zh) | 2003-07-09 | 2010-07-28 | 帕拉特克药品公司 | 取代的四环素化合物 |
CA2531732C (en) * | 2003-07-09 | 2012-04-10 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
US20050119163A1 (en) * | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
US8193227B2 (en) | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
CN1913886B (zh) * | 2003-12-15 | 2011-08-17 | 先灵公司 | 杂环天冬氨酰蛋白酶抑制剂 |
EA013904B1 (ru) | 2003-12-18 | 2010-08-30 | Янссен Фармацевтика Н.В. | Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов |
DE602004019815D1 (de) | 2003-12-22 | 2009-04-16 | Gilead Sciences Inc | 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung |
MXPA06015108A (es) | 2004-07-06 | 2007-03-26 | Abbott Lab | Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana. |
EA019419B1 (ru) | 2004-07-27 | 2014-03-31 | Джилид Сайэнс, Инк. | Фосфонатные аналоги соединений ингибиторов вич, фармацевтическая композиция и набор, их включающие, и способ лечения нарушений, ассоциированных с вич |
US7388008B2 (en) * | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
ATE417823T1 (de) * | 2004-08-02 | 2009-01-15 | Ambrilia Biopharma Inc | Verbindungen auf lysinbasis |
WO2006024490A2 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Methods and compositions for the treatment of cell proliferation |
JP2008521862A (ja) | 2004-12-01 | 2008-06-26 | デブジェン エヌブイ | イオンチャンネル、特にkvファミリーのイオンチャンネルと相互作用する5−カルボキサミド置換チアゾール誘導体 |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
EP1969940A3 (en) | 2004-12-17 | 2008-12-10 | Devgen NV | Nematicidal compositions |
ES2337496T3 (es) * | 2005-01-19 | 2010-04-26 | Rigel Pharmaceuticals, Inc. | Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos. |
JP2008533017A (ja) * | 2005-03-11 | 2008-08-21 | スミスクライン ビーチャム コーポレーション | Hivプロテアーゼ阻害薬 |
AR053845A1 (es) | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450 |
US20060287316A1 (en) * | 2005-04-27 | 2006-12-21 | Ambrilia Biopharma Inc. | Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
WO2007045496A1 (en) | 2005-10-21 | 2007-04-26 | Universiteit Antwerpen | Novel urokinase inhibitors |
AR058238A1 (es) | 2005-11-28 | 2008-01-23 | Tibotec Pharm Ltd | Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih |
TWI385173B (zh) | 2005-11-28 | 2013-02-11 | Tibotec Pharm Ltd | 作為hiv蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物 |
US8227450B2 (en) * | 2005-11-30 | 2012-07-24 | Ambrilia Biopharma Inc. | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
EP2289909B1 (en) | 2005-11-30 | 2014-10-29 | AbbVie Inc. | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
EP1968990B1 (en) * | 2005-12-27 | 2015-02-11 | Otsuka Pharmaceutical Co., Ltd. | Water-soluble benzoazepine compound and its pharmaceutical composition |
BRPI0714211B8 (pt) | 2006-07-13 | 2021-05-25 | Janssen Pharmaceutica Nv | derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende |
RU2009112716A (ru) | 2006-09-08 | 2010-10-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Соединения и способы для агентов, меченых 18f |
CN102083793A (zh) | 2006-09-21 | 2011-06-01 | 安布林生物制药公司 | 蛋白酶抑制剂 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
CN101631568B (zh) * | 2007-03-12 | 2012-08-22 | 尼克塔治疗公司 | 低聚物-蛋白酶抑制剂偶联物 |
WO2009016132A1 (en) | 2007-07-27 | 2009-02-05 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
EP2053033A1 (en) | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
CA2716079C (en) | 2008-03-10 | 2018-01-16 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
US9095620B2 (en) * | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
ES2393962T3 (es) | 2008-07-08 | 2013-01-03 | Gilead Sciences, Inc. | Sales de compuestos inhibidores del VIH. |
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
WO2010134045A1 (en) * | 2009-05-20 | 2010-11-25 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
EP2440249A2 (en) | 2009-06-12 | 2012-04-18 | Nektar Therapeutics | Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety |
WO2011033469A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Process for the preparation of fosamprenavir calcium |
WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
US20120232640A1 (en) | 2009-11-19 | 2012-09-13 | Blue Medical Devices Bv | Narrow profile composition-releasing expandable medical balloon catheter |
WO2011085130A1 (en) | 2010-01-07 | 2011-07-14 | Pliva Hrvatska D.O.O. | Solid state forms of fosamprenavir calcium salt and process for preparation thereof |
SI3127542T1 (sl) | 2010-01-27 | 2018-11-30 | Viiv Healthcare Company | Antivirusna terapija |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
US20110224443A1 (en) * | 2010-03-15 | 2011-09-15 | Venkata Naga Brahmeshwara Rao Mandava | Preparation of fosamprenavir calcium |
WO2011114212A1 (en) | 2010-03-19 | 2011-09-22 | Lupin Limited | Ammonium, calcium and tris salts of fosamprenavir |
EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
WO2011141515A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Diagnostic agents for amyloid beta imaging |
WO2011158259A1 (en) | 2010-06-18 | 2011-12-22 | Matrix Laboratories Ltd | Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
US8877947B2 (en) * | 2010-09-10 | 2014-11-04 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
WO2012085625A1 (en) | 2010-12-21 | 2012-06-28 | Lupin Limited | Process for the preparation of fosamprenavir calcium and intermediate used in its preparation |
JP2014513044A (ja) * | 2011-02-10 | 2014-05-29 | マイラン ラボラトリーズ リミテッド | ホスアンプレナビルカルシウム結晶およびその調製方法 |
SG10201800715PA (en) | 2011-06-21 | 2018-02-27 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
EP3366312A1 (en) | 2011-06-23 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Serpina 1 sirnas: compositions of matter and methods of treatment |
WO2013009844A2 (en) * | 2011-07-11 | 2013-01-17 | Purdue Research Foundation | C-3 substituted bicyclooctane based hiv protease inhibitors |
WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
IN2012DE00082A (et) | 2012-01-10 | 2015-05-01 | Council Scient Ind Res | |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
EP2700396A3 (en) | 2012-06-20 | 2015-04-29 | Sylphar Nv | Strip for the delivery of oral care compositions |
WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
AU2013340559B2 (en) | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
KR102096014B1 (ko) | 2012-12-05 | 2020-04-03 | 알닐람 파마슈티칼스 인코포레이티드 | PCSK9 iRNA 조성물 및 그 사용 방법 |
SI2970974T1 (sl) | 2013-03-14 | 2017-12-29 | Alnylam Pharmaceuticals, Inc. | Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe |
TW202342750A (zh) | 2013-05-22 | 2023-11-01 | 美商阿尼拉製藥公司 | TMPRSS6 iRNA組成物及其使用方法 |
AU2014268509B2 (en) | 2013-05-22 | 2020-10-01 | Alnylam Pharmaceuticals, Inc. | Serpina1 iRNA compositions and methods of use thereof |
KR20210158880A (ko) | 2013-12-12 | 2021-12-31 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 iRNA 조성물 및 이의 이용 방법 |
CN113057959A (zh) | 2014-02-11 | 2021-07-02 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
JP6811094B2 (ja) | 2014-05-22 | 2021-01-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | アンジオテンシノーゲン(AGT)iRNA組成物およびその使用 |
WO2016003450A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Pkc-epsilon inhibitors |
WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
BR112017000528A2 (pt) | 2014-07-11 | 2017-11-14 | Gilead Sciences Inc | moduladores dos receptores toll-like para o tratamento do hiv |
EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
WO2016069955A1 (en) | 2014-10-29 | 2016-05-06 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of hiv protease |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
AU2015350120B2 (en) | 2014-11-17 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
MX2017013102A (es) | 2015-04-13 | 2018-02-23 | Alnylam Pharmaceuticals Inc | Composiciones de ácido ribonucleico de interferencia (arni) de angiopoyetina-tipo 3 (angptl3) y método de uso de las mismas. |
US10603334B2 (en) | 2015-04-28 | 2020-03-31 | NewSouth Innovation Pty. Limited | Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity |
WO2016179342A2 (en) | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
WO2017048727A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
WO2017100236A1 (en) | 2015-12-07 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法 |
WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
TW202317151A (zh) | 2016-12-16 | 2023-05-01 | 美商阿尼拉製藥公司 | 使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法 |
WO2018206760A1 (en) | 2017-05-11 | 2018-11-15 | Remynd N.V. | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders |
CN111107850A (zh) | 2017-07-21 | 2020-05-05 | Viiv保健公司 | 用于治疗hib感染和aids的方案 |
EP3661937B1 (en) | 2017-08-01 | 2021-07-28 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections |
US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
WO2020036862A1 (en) | 2018-08-13 | 2020-02-20 | Alnylam Pharmaceuticals, Inc. | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
EP3911335A1 (en) | 2019-01-16 | 2021-11-24 | Genzyme Corporation | Serpinc1 irna compositions and methods of use thereof |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
EP4110777A1 (en) | 2020-02-24 | 2023-01-04 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Pyrrolopyridine and imidazopyridine antiviral compounds |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
EP4267579A1 (en) | 2020-12-22 | 2023-11-01 | Luxembourg Institute of Health (LIH) | Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases |
US20240002351A1 (en) | 2021-03-04 | 2024-01-04 | Universiteit Antwerpen | Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer |
WO2022253785A2 (en) | 2021-05-31 | 2022-12-08 | Universität Heidelberg | Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof |
WO2023021132A1 (en) | 2021-08-18 | 2023-02-23 | Katholieke Universiteit Leuven | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
WO2024062043A1 (en) | 2022-09-21 | 2024-03-28 | Universiteit Antwerpen | Substituted phenothiazines as ferroptosis inhibitors |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743722A (en) | 1971-07-14 | 1973-07-03 | Abbott Lab | Anti-coagulant isolation |
FR2459235A1 (fr) | 1979-06-14 | 1981-01-09 | Sanofi Sa | Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique |
JPS5946252A (ja) | 1982-09-09 | 1984-03-15 | Dainippon Ink & Chem Inc | 含フツ素アミノカルボキシレ−トおよびその製法 |
JPS5948449A (ja) | 1982-09-13 | 1984-03-19 | Dainippon Ink & Chem Inc | 直鎖状含フツ素アニオン化合物およびその製造方法 |
JPS6171830A (ja) | 1984-09-17 | 1986-04-12 | Dainippon Ink & Chem Inc | 界面活性剤組成物 |
US4616088A (en) | 1984-10-29 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitor |
US4629724A (en) | 1984-12-03 | 1986-12-16 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitors |
DE3635907A1 (de) | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
GB2200115B (en) | 1987-01-21 | 1990-11-14 | Sandoz Ltd | Novel peptide derivatives, their production and use |
CA1340588C (en) | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
IL91780A (en) | 1988-10-04 | 1995-08-31 | Abbott Lab | History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them |
WO1990007329A1 (en) | 1989-01-06 | 1990-07-12 | The Regents Of The University Of California | Selection method for pharmacologically active compounds |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5151438A (en) | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
IE902295A1 (en) | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
HUT64738A (en) | 1990-06-01 | 1994-02-28 | Du Pont Merck Pharma | Process for preparing 1,4-diamino-2,3-dihydroxi-butane compounds and pharmaceutical compositions contianing them |
TW225540B (et) | 1990-06-28 | 1994-06-21 | Shionogi & Co | |
ES2243959T3 (es) | 1990-11-19 | 2005-12-01 | Monsanto Company | Inhibidores de proteasas retrovirales. |
CA2096407C (en) | 1990-11-19 | 2007-10-02 | Kathryn Lea Reed | Retroviral protease inhibitors |
DE69126987T2 (de) | 1990-11-19 | 1998-03-05 | Monsanto Co | Retrovirale protease-inhibitoren |
HU9301445D0 (en) | 1990-11-19 | 1993-11-29 | Monsanto Co | Inhibitors of retrovirus protease |
IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
NZ244986A (en) | 1991-11-08 | 1995-10-26 | Merck & Co Inc | Hiv protease inhibitor and pharmaceutical compositions |
EP0641333B1 (en) | 1992-05-20 | 1996-08-14 | G.D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
EP1447398A1 (en) | 1992-05-21 | 2004-08-18 | Monsanto Company | Retroviral protease inhibitors |
CA2142998C (en) | 1992-08-25 | 2008-01-29 | Michael L. Vazquez | N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors |
RU2146668C1 (ru) | 1992-08-25 | 2000-03-20 | Джи Ди Сирл энд Компани | Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидное соединение, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз |
DE122007000045I2 (de) | 1992-08-25 | 2011-07-21 | Gd Searle Llc Gd Searle Llc | Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen. |
EP0610487B1 (de) * | 1992-09-03 | 1999-11-10 | Boehringer Ingelheim Pharma KG | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
US5783701A (en) * | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
TW372972B (en) | 1992-10-23 | 1999-11-01 | Novartis Ag | Antiretroviral acyl compounds |
EP0885881B1 (en) | 1992-10-30 | 2003-03-12 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
DE69331421T2 (de) | 1992-10-30 | 2002-08-01 | Searle & Co | N-substituierte Hydroxyethylaminosulfamidsäure-Derivate verwendbar als Inhibitoren retroviraler Proteasen |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
AU6135294A (en) | 1993-02-12 | 1994-08-29 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
TW281669B (et) | 1993-02-17 | 1996-07-21 | Chugai Pharmaceutical Co Ltd | |
EP0715618B1 (en) | 1993-08-24 | 1998-12-16 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
IL110898A0 (en) | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
IL111584A0 (en) | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
US5527829A (en) | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
DE19506742A1 (de) | 1995-02-27 | 1996-08-29 | Bayer Ag | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5750493A (en) | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US5646180A (en) | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
US6180634B1 (en) | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
ID25551A (id) * | 1997-12-24 | 2000-10-12 | Vertex Pharma | Bahan baku obat penghambat protease aspartil |
CO5261510A1 (es) * | 1999-02-12 | 2003-03-31 | Vertex Pharma | Inhibidores de aspartil proteasa |
-
1997
- 1997-12-24 US US08/998,050 patent/US6436989B1/en not_active Expired - Lifetime
-
1998
- 1998-03-09 AP APAP/P/2000/001850A patent/AP1172A/en active
- 1998-03-09 PL PL342113A patent/PL202845B1/pl unknown
- 1998-03-09 KR KR10-2000-7007113A patent/KR100520737B1/ko not_active IP Right Cessation
- 1998-03-09 WO PCT/US1998/004595 patent/WO1999033815A1/en active Application Filing
- 1998-03-09 CZ CZ20002363A patent/CZ301653B6/cs not_active IP Right Cessation
- 1998-03-09 CN CNB988132338A patent/CN100503589C/zh not_active Expired - Lifetime
- 1998-03-09 IL IL13694198A patent/IL136941A0/xx active IP Right Review Request
- 1998-03-09 BR BR9814480-4A patent/BR9814480A/pt not_active Application Discontinuation
- 1998-03-09 HU HU0101831A patent/HU229596B1/hu active Protection Beyond IP Right Term
- 1998-03-09 SK SK966-2000A patent/SK287123B6/sk not_active IP Right Cessation
- 1998-03-09 TR TR2000/02615T patent/TR200002615T2/xx unknown
- 1998-03-09 CN CNA2009101453192A patent/CN101565412A/zh active Pending
- 1998-03-09 ID IDW20001413A patent/ID24962A/id unknown
- 1998-03-09 EA EA200000703A patent/EA003509B1/ru not_active IP Right Cessation
- 1998-03-09 ME MEP-820/08A patent/MEP82008A/xx unknown
- 1998-03-09 RS YU39800A patent/RS52483B/en unknown
- 1998-03-09 NZ NZ505776A patent/NZ505776A/xx not_active IP Right Cessation
- 1998-03-09 AU AU65466/98A patent/AU755087B2/en not_active Expired
- 1998-03-09 EE EEP200000385A patent/EE04466B1/et unknown
- 1998-03-10 DE DE122008000021C patent/DE122008000021I2/de active Active
- 1998-03-10 PT PT98104292T patent/PT933372E/pt unknown
- 1998-03-10 JP JP05870598A patent/JP3736964B2/ja not_active Expired - Lifetime
- 1998-03-10 CA CA002231700A patent/CA2231700C/en not_active Expired - Lifetime
- 1998-03-10 EP EP98104292A patent/EP0933372B1/en not_active Expired - Lifetime
- 1998-03-10 AT AT98104292T patent/ATE382042T1/de active
- 1998-03-10 DK DK98104292T patent/DK0933372T3/da active
- 1998-03-10 ES ES98104292T patent/ES2299193T3/es not_active Expired - Lifetime
- 1998-03-10 EP EP07024817A patent/EP1944300A3/en not_active Withdrawn
- 1998-03-10 SI SI9830903T patent/SI0933372T1/sl unknown
- 1998-03-10 DE DE69838903T patent/DE69838903T2/de not_active Expired - Lifetime
- 1998-09-03 UA UA2000074456A patent/UA72733C2/uk unknown
- 1998-12-22 TW TW087121460A patent/TW486474B/zh not_active IP Right Cessation
- 1998-12-22 MY MYPI98005827A patent/MY131525A/en unknown
- 1998-12-23 PE PE1998001275A patent/PE20000048A1/es not_active IP Right Cessation
- 1998-12-23 AR ARP980106679A patent/AR017965A1/es active IP Right Grant
- 1998-12-23 CO CO98076458A patent/CO4990992A1/es unknown
- 1998-12-23 ZA ZA9811830A patent/ZA9811830B/xx unknown
-
2000
- 2000-02-03 HK HK00100695A patent/HK1021737A1/xx not_active IP Right Cessation
- 2000-06-22 IL IL136941A patent/IL136941A/en not_active IP Right Cessation
- 2000-06-22 IS IS5546A patent/IS2817B/is unknown
- 2000-06-23 OA OA1200000187A patent/OA11468A/en unknown
- 2000-06-23 US US09/602,494 patent/US6559137B1/en not_active Expired - Lifetime
- 2000-06-23 NO NO20003304A patent/NO326265B1/no not_active IP Right Cessation
- 2000-07-24 BG BG104631A patent/BG64869B1/bg unknown
-
2003
- 2003-02-19 US US10/370,171 patent/US6838474B2/en not_active Expired - Lifetime
-
2004
- 2004-10-04 US US10/958,223 patent/US7592368B2/en not_active Expired - Fee Related
-
2005
- 2005-07-13 JP JP2005205007A patent/JP4282639B2/ja not_active Expired - Lifetime
-
2008
- 2008-03-26 NL NL300339C patent/NL300339I2/nl unknown
- 2008-04-02 LU LU91426C patent/LU91426I2/fr unknown
- 2008-04-17 FR FR08C0015C patent/FR08C0015I2/fr active Active
-
2009
- 2009-01-27 JP JP2009016033A patent/JP2009102400A/ja not_active Withdrawn
- 2009-04-22 NO NO2009008C patent/NO2009008I2/no not_active IP Right Cessation
- 2009-07-16 US US12/504,243 patent/US20100124543A1/en not_active Abandoned
-
2014
- 2014-07-18 HU HUS1400042C patent/HUS1400042I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200000385A (et) | Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitorid | |
NO20006405D0 (no) | Sulfonamidinhibitorer for aspartylprotease | |
NO995433D0 (no) | Protease-inhibitorer | |
EE9700266A (et) | Aspartüüli proteaasi THF-i sisaldavad sulfoonamiidinhibiitorid | |
NO20012980L (no) | Proteaseinhibitorer | |
EE200000386A (et) | Aspartüülproteaasi inhibiitorite eelravimid | |
ATE325091T1 (de) | Aspartyl-protease inhibitoren | |
ATE259352T1 (de) | Cysteine protease inhibitoren | |
ATE231132T1 (de) | Heterocyclische metalloprotease inhibitoren | |
ATE264339T1 (de) | Serine protease inhibitoren | |
DK0923561T3 (da) | Heterocykliske metalloproteaseinhibitorer | |
NO993587L (no) | Sulfonamid-metalloprotease-inhibitorer | |
NO995434D0 (no) | Proteaseinhibitorer | |
NO994103D0 (no) | Reverse hydroksamatderivater som metallproteaseinhibitorer | |
NO995435D0 (no) | Protease-inhibitorer | |
NO995268D0 (no) | Proteaseinhibitorer | |
ATE277074T1 (de) | Serine-protease-inhibitoren | |
DE69714222D1 (de) | Serine-protease-inhibitoren | |
NO20011654D0 (no) | Benzamidderivater som trombininhibitorer | |
MA26429A1 (fr) | Inhibiteurs de protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |